Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166695 | 0.99 | MEN1 (0.60) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3603158 | 0.78 | SMO (0.67) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL4161276 | 0.78 | MAPT (0.64) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3211123 | 0.77 | POLB (0.68) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL1728824 | 0.77 | POLB (0.67) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL9105524 | 0.76 | POLB (0.75) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL13930739 | 0.74 | MAPT (0.78) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL5792352 | 0.73 | SMN1; SMN2 (0.54) | MEN1KMT2AMAPTSMN1; SMN2CNR2 | |
| SCHEMBL14136353 | 0.73 | SMN1; SMN2 (0.70) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL3075661 | 0.72 | CNR2 (0.67) | MEN1KMT2AMAPTSMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| EP-1981849-A1 | HETEROCYCLIC COMPOUNDS | LEK Pharmaceuticals D.D. (SI) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007073935-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | CYP51A1, DHCR7, LSS | SIGMAR1 1948/4885MEN1 1408/4885KMT2A 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.